GlassScriptPhysician profile
Mehul Shah
NPI 1851583819
$6,420.08
in general payments reported to CMS, 2019-2025
13 companies · $118 in 2025
The $118 reported for 2025 was less than what a typical Sports Medicine (Orthopaedic Surgery) provider received nationally (typical 2025 total: $686).
See the full distribution for Sports Medicine (Orthopaedic Surgery)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,777 · 2021: $86.12 · 2022: $235 · 2023: $159 · 2024: $1,045 · 2025: $118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $895 · Travel and Lodging: $427.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $894.68 |
| Travel and Lodging | $427.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gotham Surgical Solutions & Devices, INC. | $4,248.01 | 2019-2021 | |
| Arthrex, INC. | $610.43 | 2024 | Arthrex |
| Suvon Surgical LLC | $372.90 | 2023-2024 | |
| Joint Restoration Foundation, INC. | $289.48 | 2019 | |
| Depuy Synthes Sales INC. | $193.52 | 2019-2025 | Monovisc |
| Miach Orthopaedics, INC. | $161.34 | 2024 | |
| Covidien LP | $143.30 | 2019 | |
| Lifenet Health | $122.68 | 2022 | |
| Alnylam Pharmaceuticals INC. | $94.91 | 2025 | Amvuttra |
| Zimmer Biomet Holdings, INC. | $68.01 | 2022-2024 | Gel-One Cross-Linked Hyaluronate |
| Siemens Medical Solutions USA, INC. | $65.29 | 2021 | |
| Tersera Therapeutics LLC | $34.58 | 2023 | Xermelo |
| Fidia Pharma USA INC. | $15.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mehul Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.